Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis

@article{Mok2016ImmunogenicityOA,
  title={Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis},
  author={Chi Chiu Mok and Wen-Chan Tsai and Der-Yuan Chen and James Cheng‐Chung Wei},
  journal={Expert Opinion on Biological Therapy},
  year={2016},
  volume={16},
  pages={201 - 211}
}
  • C. Mok, W. Tsai, +1 author J. Wei
  • Published 1 February 2016
  • Medicine, Biology
  • Expert Opinion on Biological Therapy
ABSTRACT Introduction: The use of biologic disease-modifying anti-rheumatic drugs (DMARDs), including therapeutic antibodies, antibody fragments and protein constructs that target key mediators in the pathophysiology of rheumatoid arthritis (RA), has improved the chance of achieving low disease activity and clinical remission. However, individual patients respond differently to biologic DMARD therapy, particularly the tumor necrosis factor (TNF) inhibitors. Areas covered: While the variation of… 
View on Taylor & Francis
web.csh.org.tw
29 Citations
Highly Influential Citations
3
Background Citations
9
Results Citations
2

29 Citations

Citation Type

Citation Type

The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature
TLDR
Similar to observations in other rheumatic diseases, the incidence of ADA formation to biologic agents in patients with PsA is often decreased when patients are given concomitant treatment with disease-modifying anti-rheumatic drugs, suggesting that the immune response is a characteristic of the biologic agent.
Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications.
TLDR
The kinetics of anti-TNF biologics, and consequent therapeutic implications, are examined, and some latest developments in the field are overviewed.
The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis
TLDR
There is a broad spectrum of possible adverse events associated with TNFi treatment, ranging from mild to serious, and with diverse clinical manifestations, however, most adverse events may be minimized by appropriate screening before starting treatment and with ongoing surveillance to ensure an early diagnosis.
High titers of ADAbs in rheumatic disease patients undergoing anti-TNF therapy is not associated with lupus-like autoimmunity
TLDR
It is shown that in patients with inflammatory arthritis treated with the currently used anti-TNFs, the development of auto-antibodies is not associated with theDevelopment of ADAbs, suggesting that anti-drug immunogenicity and autoimmunity are not related.
Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study
TLDR
In patients with RA or SpA and secondary failure, the development of ADA against ADL or INF, but not ETN, appears to be one of the main reasons for secondary treatment failure,but not the only one.
Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
TLDR
The optimization of biologic therapies by taking into proper account the following issues would improve patient outcomes: anti-drug antibody (ADAb) formation, suspicion and management of infections, lupus-like syndrome, effects on bone mass and sexual sphere, and relationship between RA and periodontal disease (PD.
Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction: what have we learned over the last year about tumor necrosis factor inhibitors in rheumatoid arthritis?
Purpose of reviewThis article reviews the most current studies investigating the use of tumor necrosis factor inhibitors (TNFis) in the treatment of rheumatoid arthritis. Recent findingsStudies over…
Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study
TLDR
Investigation of the prevalence of anti-infliximab (IFX) antibodies in patients with Behçet syndrome found that they do not seem to be a frequent problem in patients treated with IFX, but may be associated with relapses and infusion reactions, when present.
Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences
TLDR
This article reviews the various clinical situations where it may be important to use a particular anti-TNF agent and gives their expert opinion and future perspectives on the area.
Tumor Necrosis Factor-Alpha Inhibitory Therapy for Non-Infectious Autoimmune Uveitis
TLDR
Patients receiving anti-TNF-α therapy may experience adverse events and should be closely monitored for the development of opportunistic infections, reactivation of tuberculosis and hepatitis, demyelinating disease and neuropathies, as well as malignancies.
...
1
2
3
...

References

SHOWING 1-10 OF 96 REFERENCES
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
TLDR
The evidence to date on the effect of immunomodulatory therapy when co-administered with anti-TNFs is reviewed and whether such a strategy should be employed in SpA and psoriasis is discussed, and if optimization of the MTX dose could improve biologic drug survival and thereby benefit disease management.
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
TLDR
Serologic monitoring of infliximab bioavailability and immunogenicity in individual patients would be useful in optimizing treatment regimens to improve efficacy and tolerability, and development of anti-infliximab antibodies is associated with increased risk of infusion reaction and treatment failure.
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
TLDR
A model wherein monitoring of drug levels and ADAb may be a predictive tool leading to a better choice of biologics is proposed, which could improve chronic inflammatory disease management toward a personalized and more cost-effective approach.
The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
TLDR
Concomitant immunomodulators in the form of methotrexate or azathioprine reduced the immunogenicity of therapeutic antibodies in rheumatoid arthritis, Crohn disease, and juvenile idiopathic arthritis.
Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms.
TLDR
The results indicate that IL10 polymorphisms are associated with increased formation of antibodies against adalimumab in RA patients, and these observations are consistent with the reported association of the G8 microsatellite allele with formation of antibody to recombinant FVIII in hemophilia and to nAChR in MG.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
TLDR
In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotRexate provided clinical benefit and halted the progression of joint damage.
Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
TLDR
It is concluded that the presence of neutralizing antibodies is associated with lower serum levels of the anti-TNFα biologics, leading to lower efficacy and higher withdrawal rate.
Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment.
  • P. Emery
  • Medicine, Biology
    Rheumatology
  • 2012
TLDR
Results with the majority of non-TNF inhibitors suggest that their administration may provide a greater proportion of patients with an effective, evidence-based disease-modifying approach earlier in the course of their disease than switching TNF inhibitors.
Dealing with immunogenicity of biologicals: assessment and clinical relevance
TLDR
It has been shown that immunogenicity against biologicals can be persistent or transient, and monitoring of drug levels as well as of antibodies against therapeutic antibodies may lead to more rational treatment strategies.
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
TLDR
The clinical response to two anti-TNFα biological agents closely follows the trough drug levels and the presence of antibodies directed against the drugs.
...
1
2
3
4
5
...